Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Selects Velesco to Manufacture Kits

NEW YORK (GenomeWeb News) – Rubicon Genomics today said that Velesco Pharmaceutical Services will manufacture its Transplex kits that it will supply for use with Agendia's breast cancer diagnostics.

Last week, Rubicon said that Agendia would use its whole-genome RNA amplification technology with Agendia's breast cancer diagnostic tests. Under the deal, Agendia will incorporate Rubicon's TransPlex technology into the analysis of formalin fixed, paraffin-embedded patient samples for use in testing with its Symphony suite of breast cancer diagnostics.

Rubicon noted today that cGMP production of the TransPLEX kits is required for FDA clearance of the tests.

"Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up," Rubicon CEO James Koziarz said in a statement. "We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business."

Financial and other terms of the agreement were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.